股动脉内膜剥脱联合腔内(杂交)或旁路术治疗股腘闭塞性病变的结局比较
基于NSQIP 2012-2017年数据,纳入4478例非急诊股总动脉内膜剥脱联合股浅动脉腔内介入或旁路术患者,倾向加权分析比较杂交与人工血管旁路、杂交与大隐静脉旁路。杂交与两种旁路在全身并发症和死亡上无差异;旁路组感染、脓毒症、再入院及任何并发症复合终点更高。
要点
- 杂交与人工血管旁路在全身并发症和死亡上无差异。
- 人工血管旁路深部手术部位感染、脓毒症、30天再入院及任何并发症更高。
- 大隐静脉旁路浅表手术部位感染及任何并发症复合终点更高。
核心结论
- 对于跛行患者,旁路术较杂交术式全身并发症更多,但其他指征下开放重建与杂交在全身并发症和死亡风险上无增加。
- 旁路组感染、术后输血和再入院等其他并发症更常见。
研究设计与样本
- 回顾性队列研究,查询NSQIP 2012-2017年数据。
- 纳入非急诊股总动脉内膜剥脱联合股浅动脉腔内介入或旁路术患者共4478例(杂交1537例、人工血管旁路1408例、静脉旁路1533例)。
- 进行两项倾向加权分析:杂交与人工血管旁路比较、杂交与静脉旁路比较。
主要发现
- 杂交与人工血管旁路比较:全身并发症OR=1.29(95%CI 0.95-1.76,P=0.107),死亡OR=1.54(95%CI 0.71-3.33,P=0.275)。
- 人工血管旁路与杂交比较:深部手术部位感染OR=2.02(95%CI 1.19-3.45,P=0.010),术后脓毒症OR=2.07(95%CI 1.13-3.76,P=0.018),非计划30天再入院OR=1.28(95%CI 1.04-1.58,P=0.021),任何并发症复合OR=1.38(95%CI 1.18-1.61,P<0.001)。
- 杂交与静脉旁路比较:全身并发症OR=1.10(95%CI 0.81-1.49,P=0.552),死亡OR=0.91(95%CI 0.42-2.00,P=0.819)。
- 静脉旁路与杂交比较:浅表手术部位感染OR=1.45(95%CI 1.04-2.02,P=0.028),任何并发症复合OR=1.32(95%CI 1.13-1.54,P=0.001)。
- 发生全身并发症患者总体死亡率显著更高(13.9% vs 0.1%,P<0.001)。
临床怎么用
- 跛行患者选择杂交术式可能减少全身并发症。
- 旁路术需关注感染、输血和再入院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The gold-standard for management of combined common femoral artery (CFA) and superficial femoral artery (SFA) atherosclerotic occlusive disease has traditionally been open femoral endarterectomy and femoral-popliteal bypass. Hybrid approaches involving an open and endovascular component are increasingly common. The aim of this study was to compare perioperative outcomes in patients who underwent an open versus hybrid revascularization. METHODS: NSQIP data, years 2012-2017, were queried for patients who underwent nonemergent CFA endarterectomy with either SFA transluminal intervention or bypass. The primary outcome of interest was a composite of cardiovascular, pulmonary, and renal complications (systemic) and mortality. Two propensity-weight adjusted analyses were performed: 1) comparing hybrid and prosthetic bypass 2) comparing hybrid and vein bypass. RESULTS: There were 4,478 patients included (1,537 hybrid, 1,408 prosthetic, 1,533 vein); 64.8% were men, and the mean age was 67.8 ± 9.7 years; 29.9% had claudication, 38.8% had tissue loss, and 31.3 were unspecified. In the propensity-weighted analysis comparing hybrid to prosthetic bypass, there was no difference in systemic complications (OR = 1.29 for prosthetic vs. hybrid; 95% CI: 0.95-1.76; P = 0.107) or mortality (OR = 1.54; 95% CI: 0.71-3.33; P = 0.275). Prosthetic bypass was associated with more deep surgical-site infections (OR = 2.02; 95% CI: 1.19-3.45; P = 0.010), postoperative sepsis (OR = 2.07; 95% CI: 1.13-3.76; P = 0.018), unplanned 30-day readmission (OR = 1.28; 95% CI: 1.04-1.58; P = 0.021), and the composite of any complication (OR = 1.38; 95% CI: 1.18-1.61; P < 0.001). In the propensity-weighted analysis comparing hybrid to vein bypass, there was no difference in systemic complications (OR = 1.10 for vein vs. hybrid; 95% CI: 0.81-1.49; P = 0.552) or mortality (OR = 0.91; 95% CI: 0.42-2.00; P = 0.819). Vein bypass was associated with more superficial surgical-site infections (OR = 1.45; 95% CI: 1.04-2.02; P = 0.028), and the composite of any complication (OR = 1.32; 95% CI: 1.13-1.54; P = 0.001). Overall mortality was significantly higher patients with systemic complications (13.9% vs 0.1%; P < 0.001). Systemic complications were less common in patients with claudication undergoing hybrid revascularization than vein or prosthetic bypass. CONCLUSIONS: Claudicants undergoing bypass experienced more systemic complications than those undergoing hybrid procedures, but there appears to be no increased risk of systemic complications or mortality with open reconstruction when compared to hybrid procedures for other indications. Other complications, such as infection, postoperative transfusion, and readmission, were more common in the bypass groups.
引用
- DeCarlo C, Boitano LT, Sumpio B, et al. Comparative Analysis of Outcomes in Patients Undergoing Femoral Endarterectomy plus Endovascular (Hybrid) or Bypass for Femoropopliteal Occlusive Disease. Ann Vasc Surg. 2020. PMID: 32927041. doi:10.1016/j.avsg.2020.08.143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。